a first after proved team. Mike, widespread Option members, sluggishness morning, the good and everyone. initial and Health productive very team the of to year Overall, our for patients, omicron due impacts to be variant Thanks, to start Care on customers, the quarter the
to to invest provide we ensure unsurpassed environment navigating while patient economic continue We challenging in our strategy, future the care. growth
of to half quite as year vaccine in see this we first XXXX. the quarter our metrics pleased quarter were As operational spectrum results will second to note year, financial by the the prior was Mike across starting first that very soft the use financial of the performance of comparable strong COVID distribution we quarter Specific just in minutes, of period few I manage to our a the first were and am review enterprise. and
not leverage we the We from benefits P&L that also drive expense do a believe to repeat. year one-time are helped in benefited this likely that few
So the out quarter, to in very will growth we quarter, our the the the we anticipated, Nonetheless, a believe will of while are normalizing comps our out growth we financial and extent. raising is coming for guidance Mike greater in first discuss on reported based profile our half year momentum strong shortly. first balance anticipate accordingly as the we back as
were As disruptive in operation. very the patterns pharmacy the we the resurgence of referral local our we impact COVID the entered related variant. midst year, and This had on omicron to a
we able after Given quarter. the in saw resilience field, were of end subsided the respond the to omicron by quickly and of we normal first cases our the in teams recurrence operations the a
referral volumes in reopening certain gradual few sources. a While many referral to a we our did of in lag geographies, continued see
driven chronic and the muscular and chronic was strong was quarter inflammatory Our multiple especially others. in and our revenue of newer therapies myasthenia therapies dystrophy gravis, for portfolio by sclerosis,
growth We thyroid therapies year available also last points supply for were short in a therapies including few saw now eye that of are disease. from
the across earnings our with pressures services utilize. on goods we call, prior the we entered unprecedented spectrum broad discussed year we also inflationary of As and
was the of the first year. see the in somewhat While inflationary pressures an the increased collective we muted impact balance quarter, do in
of compensation primarily our end first our to we part continued We competitiveness thoroughly labor and quarter cycle. the annual assess adjust as of at the
until after QX. So the compensation increases are not fully reflected
procurement others. key and medical increases and including categories We services supplies, plastics seeing transportation, broad in are business key also cost
the to but the inflationary situation storm focused remains pressures believe in possible, finding and day we I recruit fielding we to and As competitive while the to career team focus well, both care. sources remain to from every greatest a reasonably to the always, development of our compensation weather maintaining level industry. perspective. new labor and efficiency the clinical are members continue mitigate we team team patient is highest the while investments the ensuring will challenging, on on extent quality of making best The continue
and quarter, initiatives. progress continued on invest and the about the Nursing which believe of The acquisition growing we platform in to we making Aside we national our great a alternate also Nursing Wasatch the with which future two while of good closed provides recent infusion site experience Infusion growth or establishing tremendous is from our platform the team integrating can acquisition, are acquisitions we also learn are on Infinity patient market, in portfolio Infusion Networks Specialty a Utah recently unique excited deal. in SPNN. Pharmacy dynamics the first we We the nursing adding from to SPNN our
this believe our also will nursing amongst to the will marketplace, capabilities future differentiate growth, only therapies. in platform clinical especially chronic continue We enable help not our but
added us over including manufacturers. clinical to biopharmaceutical write has infusion was back clinics Regarding believe SPNN that organization pre-existing help the pharmacies, our cash array and to these further will to pharmacies, that natural four further expertise, started. infusion space. chronic our team presence XX platform settings our capability to With capability. am suite ability specialty With progression complementary we beginning infusion flow and serve I just team the our with on our clinical distinct built this expanded find SPNN to a and that and attractive unique acquisition, are confident a transactions executed foundation free highly establish the and our post-acute very getting script nursing Care the upon flow, of technology We to just accelerate are The have Health national expand our intensely back a had we our months, created have acquisitions has the platform in and economic seek a help model and our it a capital Reflecting for a strong broad Funded to and national the attractive and structure established. strategy, past team foundation is capabilities take unique on and is to acquisitions our focus Infinity we’ve cash our continue a the to through commercial and in very stronger customers collaboration their opportunities growth. model we clinical capabilities ambulatory of Option strategic bone. integration generation, constructive of on robust solely
team flow wrap the while in it Despite is of coming solid and continue So results over to turn variables my Mike? expect XXXX. quarter manage, bit and am to to of accelerating track track that, is very our of momentum call I’ll in a I Mike With up in and year, a year. to on we cash perpetuate comments, review that still quite to by number to record the we out the deliver the encouraged a first the detail. strong risks early growth more the